SAB BIOTHERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SAB BIOTHERAPEUTICS, INC. (SABS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 211.49 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 211.16M shares, a 627.15% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 30.77M shares, a 14.67% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 29.04M shares, a 11.85% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 36.06M shares, a 33.93% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 44.79M shares, a 24.92% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 35.86M shares, a 8.64% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 33.00M shares, a 1508.37% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 2.05M shares, a 90.54% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 211.49M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 211.16M shares 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | 44.79M shares 10-K · filed 2026-03-09 | |||||||
| 2025-09-30 | 30.77M shares 10-Q · filed 2025-11-14 | 80.77M shares 10-Q · filed 2025-11-14 | ||||||
| 2025-06-30 | 29.01M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 29.04M shares 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | 35.86M shares 10-K · filed 2026-03-09 | |||||||
| 2024-09-30 | 36.06M shares 10-Q · filed 2025-11-14 | 36.02M shares 10-Q · filed 2025-11-14 | ||||||
| 2024-06-30 | 34.86M shares 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | 32.94M shares 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | 33.00M shares 10-K · filed 2025-03-31 | 34.05M shares 10-K · filed 2024-03-29 | ||||||
| 2023-09-30 | 26.93M shares 10-Q · filed 2023-11-13 | 1.64M shares 10-Q · filed 2024-11-06 | 26.87M shares 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | 27.10M shares 10-Q · filed 2023-08-21 | 1.63M shares 10-Q · filed 2024-08-08 | 26.83M shares 10-Q · filed 2023-08-21 | |||||
| 2023-03-31 | 1.39M shares 10-Q · filed 2024-05-20 | 24.37M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 2.05M shares 10-K · filed 2024-03-29 | 20.52M shares 10-K · filed 2023-04-14 | ||||||
| 2022-09-30 | 18.96M shares 10-Q · filed 2023-11-13 | 20.14M shares 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | 19.81M shares 10-Q · filed 2023-08-21 | 20.36M shares 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | 19.61M shares 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 21.68M shares 10-K/A · filed 2023-04-28 | |||||||
| 2021-09-30 | 2.57M shares 10-Q · filed 2022-11-14 | 2.08M shares 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | 2.33M shares 10-Q · filed 2022-08-10 | 2.22M shares 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | 913.23K shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |